Brendan Technologies Chief Executive Officer to Present at IBC Life Sciences Training Academy.

CARLSBAD, Calif. -- Brendan Technologies, Inc. (OTCBB: BDTE), an innovative analytical software company, said that Dr. John Dunn, founder and chief executive officer, has been invited by the IBC Life Sciences Training Academy to provide comprehensive training courses on the subject of Analyzing Biological Assays to the biopharmaceutical industry. Dr. Dunn, one of the industry's leading experts in this field, taught six courses last year for IBC and has generated tremendous interest in this subject.

"We are looking forward to working again with IBC," stated Dr. Dunn. "We are pleased that IBC has given us the opportunity to teach courses that will help educate the biopharmaceutical community on all aspects of immunoassay testing, which is our primary business focus." For twenty years IBC Life Sciences has been supporting and supplying the life sciences industry by providing specialized information through its conferences and courses. It has established leading industry events in North America, Europe, and Asia. The courses that Dr. Dunn will be teaching are being held in San Francisco, Boston, and San Diego during the months of April, May and June.

Background on Immunoassay Testing

Immunoassays are highly sensitive and specific chemical tests used to detect and quantify extremely minute substances in blood, body fluid and other biological samples, using an immunological reaction. These tests measure the formation of antibody-antigen complexes and detect them via an indicator reaction. Their high specificity results from the use of antibodies and purified antigens as reagents. High sensitivity is achieved by using an indicator system that results in amplification of the measured product. Immunoassays may be qualitative (positive or negative) or quantitative (amount measured).

Immunoassays are one of the world's largest and fastest growing testing technologies used to diagnose diseases, discover new chemical entities and biological products, provide vital data in the development of drugs in FDA clinical trials, and assist in quality control of drug manufacturing and drug screening. It is also one of the largest technologies used in environmental testing. Currently, $50 billion is spent globally on immunoassay testing, with approximately $1 billion of that being spent on immunoassay software.

About Brendan Technologies, Inc.

Brendan Technologies, a developer and marketer of innovative analytical software, is actively providing software solutions to improve the accuracy, quality control, workflow, and regulatory compliance of immunoassay testing in laboratories in the biopharmaceutical, clinical, research, veterinarian and agricultural industries. The Company's customers, many of whom are Fortune 1000 organizations, represent some of the largest corporations in their respective fields. Brendan Technologies is currently redesigning and expanding its current product lineup to better capitalize on the growing demand of its target markets for more advanced software.

FORWARD-LOOKING STATEMENTS: This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and as such, may involve risks and uncertainties. For a discussion of such risks and uncertainties that could cause actual results to differ from those contained in the forward-looking statements, see "Risk Factors" in the Company's Annual Report on Form 10-KSB, as amended, for the most recently ended fiscal year. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, and expectations, are generally identifiable by the use of words such as "believe," "expect," "intend," "anticipate," "estimate," "project," or similar expressions. These forward- looking statements relate to, among other things, expectations of the business environment in which the Company operates, projections of future performance, potential future performance, perceived opportunities in the market, and statements regarding the Company's mission and vision. The Company's actual results, performance, and achievements may differ materially from the results, performance, and achievements expressed or implied in such forward-looking statements.